Insulin aspart (NovoRapid® FlexTouch ®)

Assessment Status Rapid Review Complete
Drug Insulin aspart
Brand NovoRapid® FlexTouch ®
Indication For the treatment of diabetes mellitus in adults, adolescents and children aged 2 years and above.
Assessment Process
Rapid review commissioned 22/07/2014
Rapid review completed 28/08/2014
Rapid review outcome Full pharmacoeconomic assessment recommended at the submitted price.

The company has not submitted a HTA dossier to the NCPE therefore the cost effectiveness of the technology could not be proven.